Please ensure Javascript is enabled for purposes of website accessibility

Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Earnings Call Transcript

By Motley Fool Transcribing – Aug 6, 2021 at 5:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ONCT earnings call for the period ending June 30, 2021.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Oncternal Therapeutics, Inc. (ONCT -0.93%)
Q2 2021 Earnings Call
Aug 05, 2021, 5:00 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Operator

Greetings, and welcome to the Oncternal Therapeutics, Incorporated's second-quarter 2021 financial results call. [Operator instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Richard Vincent, chief financial officer. Thank you.

You may begin. 

Rich Vincent -- Chief Financial Officer

Thank you, Darryl. Good afternoon, everyone, and thank you for joining us today. Joining me on this call this afternoon are our president and CEO, Dr. James Breitmeyer; and our CMO, Dr.

Salim Yazji. We welcome all of you. Today's call includes a business update, a discussion of our 2021 second-quarter financial results, as well as our upcoming milestones, which will be followed by Q&A. Today's press release and a replay of today's earnings call will be available on the investor relations section of Oncternal's website for at least the next 30 days.

10 stocks we like better than Oncternal Therapeutics, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* 

They just revealed what they believe are the ten best stocks for investors to buy right now... and Oncternal Therapeutics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

We also filed our 10-Q for the second quarter of 2021 earlier today. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We will be making forward-looking statements during this call about future events, such as our business and product development strategies and future financial and operating performance. Our actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business.

These forward-looking statements should be considered in conjunction with and are qualified by the cautionary statements contained in today's press release and our SEC filings, including our Form 10-Q for the quarter ended June 30, 2021. This conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 5, 2021. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this conference call. With that, it's my pleasure to hand the call over to our CEO, Dr.

Jim Breitmeyer.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Rich, and good afternoon, everyone. At Oncternal, we are committed to developing novel treatments for patients with cancer who have critical unmet medical needs. We're advancing a robust product pipeline with clinical and preclinical product candidates that target several such cancer indications. We are particularly pleased with the progress made during the second quarter of 2021 to advance the development of cirmtuzumab, our investigational, potentially first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1, also known as receptor tyrosine kinase-like orphan receptor one.

Encouraging updated interim clinical trial results with cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma, or MCL, and chronic lymphocytic leukemia, or CLL, were presented in a poster session at the ASCO 2021 annual meeting. In addition, in July 2021, we opened a new treatment cohort of our ongoing Phase 1/2 study to evaluate cirmtuzumab plus ibrutinib in patients with MCL who are refractory to prior BTK inhibitor treatment, including ibrutinib, acalabrutinib or zanubrutinib; and to include patients who are at high risk for progression, having had an inadequate response to ibrutinib that is only achieving stable disease or a partial response. Our CMO Salim will provide additional details on each of these. We also have an ongoing dialogue with the U.S.

FDA concerning the potential registration pathway for cirmtuzumab, and we expect further feedback on a potential pivotal study design this year. ROR1 has been an -- become an increasingly visible target in the oncology space and has been the subject of M&A activity, including the acquisition of VelosBio by Merck & Co. VLS-101, VelosBio's ROR1-targeted antibody drug conjugate, or ADC, was originally invented and developed add-on terminal, and it incorporates the cirmtuzumab antibody to target ROR1. We believe we have one of the most advanced and diverse pipelines targeting ROR1 in the industry today.

We also continue to collaborate on two investigator-sponsored clinical studies of cirmtuzumab at UC San Diego. First, a Phase 1b clinical trial of cirmtuzumab in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced unresectable breast cancer; and second, a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a BCL2 inhibitor in patients with relapsed/refractory CLL. UCSD finished enrollment for the breast cancer study in the second quarter of this year. So moving on to our immuno-oncology cell therapy programs, we continue to make progress on our novel ROR1-targeting CAR-T and CAR-NK cell therapy candidates, moving them from the laboratory toward the clinic as planned.

We are very encouraged by the advancement of our cell therapy efforts, including successful recruitment of the internal team and external scientific advisors; preclinical activities with the Karolinska Institute in Stockholm, Sweden; development and manufacturing activities with Lentigen Technology and Miltenyi Biotech; our research collaboration with UC San Diego; and our development partnership with Shanghai Pharma Limited in Greater China. We are tremendously excited by the potential of our cell therapy program targeting ROR1, which may allow for the selective targeting of tumor cells that express ROR1 while sparing healthy tissues. We also advanced the development of TK216, our investigational targeted small molecule inhibitor of the E26 transformation specific, or ETS, family of oncoproteins. We presented encouraging interim clinical data for TK216 in patients with relapsed or refractory Ewing sarcoma in an oral session at the ASCO 2021 meeting.

Based on the data, we added an expansion cohort with an optimized dosing schedule. Salim will provide additional details on this program as well. During this past quarter, we further strengthened our executive team with two key additions in the medical and business fronts. Dr.

Salim Yazji, joining us on the call now, is our new chief medical officer. Salim brings over 25 years of experience in both industry and academic settings, leading global oncology development and regulatory strategy throughout all phases of development, including various product approvals. Pablo Urbanejaas joined us as our SVP of corporate development. Pablo is a seasoned biotech professional with a solid track record in corporate strategy and licensing, and he will lead our expanding strategy portfolio and business development functions at Oncternal.

With this, I will now turn the call over to Salim to provide more color on our clinical programs.

Salim Yazji -- Chief Medical Officer

Thank you, Jim. Good afternoon, everyone. At this year's ASCO meeting, we announced updated clinical data for cirmtuzumab in combination with ibrutinib. In patients with relapsed/refractory MCL enrolled in our ongoing Phase 1/2 trial, the data cutoff at that time was April 16.

The best objective response, complete or partial response rate, or ORR, was 83% for these heavily pretreated patients with MCL treated with cirmtuzumab plus ibrutinib, which compares favorably to historical ORR of 66% for ibrutinib monotherapy. Seven of the 18 evaluable patients, or 39%, had achieved a complete response, or CR, by chip and criteria, one of which was a complete metabolic response, CMR, by pet scan. These CRs remained durable for eight to 30-plus months. This compares favorably to the historical CR rate of 20% for ibrutinib monotherapy.

The media progression-free survival, PFS, and overall survival, OS, were not reached for MCL patients. And the PFS estimate at two years was approximately 60% with a median follow-up of 18.9 months. This compares favorably to the historical PFS of ibrutinib monotherapy of approximately 30% with a median follow-up of 24 months. For patients with CLL, the ORR was 94%, and five patients had achieved the clinical criteria for complete responses with a bone marrow confirmation pending in one patient.

The median PFS and OS has not been reached for CLL patients. And the PFS estimate at two years was approximately 82% with the median follow-up of 22.1 months. The combination of cirmtuzumab and ibrutinib continues to be well-tolerated with the safety profile consistent with or slightly improved compared to the historical data for ibrutinib monotherapy. For example, in patients with MCL Grade 3 and 4 neutrofil decrease was documented in 11.5% of the patients with cirmtuzumab plus ibrutinib, compared to 29% for ibrutinib alone from its registrational study.

We and our study investigators continue to be particularly impressed by the response in heavily pretreated patients. Six patients with MCL who has relapsed following prior autologous stem cell transplant, or CAR-T, therapy, were enrolled in our study, and all six of them responded to the combination of cirmtuzumab and ibrutinib. Four patients achieved complete response, and two patients achieved partial response. All four patients who had received prior treatment with ibrutinib responded to the treatment with cirmtuzumab and ibrutinib with the two CRs and two PRs.

We continue to support our Phase 1b investigator-initiated clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced undetectable breast cancer. At AACR in April 2021, the UC San Diego investigators presented results showing an objective response rate of 57% with an encouraging toxicity profile. These results were consistent with the previously reported interim results of the study and compared favorably to the historical results of single-agent paclitaxel, particularly for patients such as these who had received a median over six prior therapy for metastatic disease. As Jim mentioned, this trial was fully enrolled for a total of 15 evaluable patients.

The results are expected to be presented at the scientific conference or publication. Also, at AACR, we presented data from preclinical study, investigating cirmtuzumab in combination with chemotherapeutic agents, cisplatin and paclitaxel, used to treat high-grade serious ovarian cancer, HGSOC, an endometrial cell line in vitro. Cirmtuzumab demonstrated single-agent activity and enhanced the anti-corrosive effect of chemotherapeutic agents in both ovarian and endometrial cancer cell models, including platinum-resistant ovarian cancer. Our program to develop TK216, our ETS family inhibitor, continues to progress.

At this year's ASCO meeting, we presented an updated clinical data from our ongoing Phase 1/2 trial of TK216 for patients whose relapsed/refractory Ewing sarcoma, and the data cut for that was April 22. The data remains consistent and confirm and extend previous results. Two patients who achieved CR remain with no evidence of disease, one for over 24 months and the other for over 14 months on a study. The treatments continue to be well-tolerated with reversible myelosuppression as the most common side effect.

Based on our encouraging data and KOLs' feedback, in July 2021, we added a new Phase 2 expansion cohort, targeting Ewing sarcoma patients to evaluate clinical response to a single-agent TK216 using an optimized dosing regimen, treating for 28 days per cycle to intensify the amount of TK216 administered over time. I will now turn the call over to Rich Vincent to review financial results and upcoming milestones. 

Rich Vincent -- Chief Financial Officer

Thank you, Salim. In October 2017, CIRM awarded an $18.3 million grant to researchers at the UC San Diego School of Medicine to advance our Phase 1/2 clinical trial, evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. We are conducting this study in collaboration with UC San Diego and expect to receive approximately $14 million in development milestones under research sub awards throughout the award period. In conjunction with this award, our grant revenue was $0.9 million for the second quarter ended June 30, 2021.

Our total operating expenses for the quarter ended June 30, 2021, were $8.6 million, including $1.8 million in noncash stock-based compensation. Research and development expenses for the quarter totaled $5.2 million. And general and administrative expenses totaled $3.4 million. Net loss for the second quarter was $7.7 million or a loss of $0.16 per share basic and diluted.

As of June 30, we had $103.7 million in cash and cash equivalents. We believe these funds will be sufficient to support our operations into 2023. As of June 30, we had 49.4 million shares of common stock outstanding. With respect to upcoming milestones for our cirmtuzumab program, we expect an interim clinical data update for the ongoing Phase 1/2 study in MCL and CLL at a scientific conference in the fourth quarter of 2021, a clinical data update from the fully enrolled ongoing breast cancer Phase 1b IST study, an FDA interaction update regarding a potential registration trial of cirmtuzumab in patients with MCL and further preclinical data in additional ROR1-expressing tumors.

On the cell therapies front, we are advancing our ROR1 CAR-T program to treat the first patient in the first half of 2022. For our TK216 program, we expect an interim clinical data update for the ongoing Phase 1/2 expansion cohort in Ewing sarcoma at a scientific conference in the fourth quarter of 2021, as well as additional preclinical data and other ETS-driven tumors. Now I will turn the call back over to Jim.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Rich. In closing, this past quarter, we presented very encouraging data from our clinical programs. We've strengthened our management team, and we continue to have a strong balance sheet and look forward to multiple potential catalysts in the coming months. Thank you for listening to our presentation today.

With that, I'll turn things back to Darryl for the Q&A portion of this afternoon's call.

Questions & Answers:


Operator

Thank you. [Operator instructions] Our first questions come from the line of Hartaj Singh with Oppenheimer. Please proceed with your questions.

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Great. Thank you, and thanks for the presentations, gentlemen. Jim, a couple of questions. One is, you sort of talked about earlier or about the potential registrational trial for cirmtuzumab and ibrutinib in MCL.

Could you talk a little bit more about what the comp tours of that could look like, whether it would be in a proper Phase 3 drug trial, Phase 2 number of patients? How large could it be? I know you might not have the full information now, but if you can just sort of give us an idea. And then, in your CAR -- your ROR1 CAR-T program, can you talk a little bit about how do you expect to undertake the manufacturing of that for your patients as you dose them? Will it be sort of localized manufacturing at the various facilities where you're giving the CAR-T? Will it be more centralized manufacturing? And then, I got a quick follow-up. Thank you. 

Jim Breitmeyer -- Chief Executive Officer

Thank you for your questions, Hartaj. So your first question regards a potential pivotal trial that we are actively discussing with the FDA. And as I said, we are hopeful that we may reach agreement on a study design during this calendar year. So certain elements are still being discussed.

But with both based on FDA feedback and discussions with KOLs and considering commercial considerations, we do believe that a randomized trial of cirmtuzumab plus ibrutinib versus ibrutinib is by far the most robust and best way to go forward toward approval. We have -- we are also carefully examining the ibrutinib response into -- for patients with MCL. And we believe that there is unmet medical need there where we could have a population of MCL patients that is more likely to progress on ibrutinib, without, we think, having a dramatic reduction in the patient population for eventual commercial rollout. And then, I'd say that we're still -- the statistics are still being discussed with FDA.

But for -- as you can imagine, for a randomized trial, it would probably be in the range of several hundred patients, let's say, low single-digit hundreds of patients, while we work out the particulars. So as far as CAR-T manufacturing is concerned, we have -- as I mentioned, we're working with Miltenyi, and they are developing a very interesting technology that would permit local and regional processing of the cells. And we are looking at, for example, the Miltenyi prodigy system, which is a closed bench-top system where many of the steps to process the T-cells from the patient can be done in a fairly common GMP facility, not requiring brick-and-mortar. So that is -- that's a leading example of what we're considering on the manufacturing side, so that we can do the processing near where the patient will be located. 

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Great, great. Thank you, Jim. And then just a quick question on the preclinical data that you're going to present in the fourth quarter of additional ROR1-expressing tumors. Is that in the solid tumor domain, liquid tumor domain? Or does -- and will you be looking combo or monotherapy there? And thank you for the questions.

Jim Breitmeyer -- Chief Executive Officer

Certainly, Hartaj. So what we -- with our -- with Pablo Urbanejaas joining of the company and his strength in strategic planning, we are doing an extensive review of a number of indications where literature or existing preclinical data suggest that ROR1 inhibition could be clinically meaningful. And it is including both solid and liquid tumors, and it's including both monotherapy and combination therapies. And so with that, we're going to put each of those indications through the ringer pressure test and determine what makes the most sense to proceed with for our upcoming clinical indication or indications. 

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Great, great. Thank you, Jim. I'll get back in the queue. 

Jim Breitmeyer -- Chief Executive Officer

Thank you, Hartaj. 

Operator

Thank you. Our next questions come from the line of Robert Burns with H.C. Wainwright. Please proceed with your questions.

Robert Burns -- H.C. Wainwright & Co. -- Analyst

Hey, guys, thanks for taking my questions, and congrats on the quarter. Just two for me, if I may. First, you have framed expectations with regard to the update we're expected to see in 4Q for cirmtuzumab plus ibrutinib in MCL. In particular, what the duration of follow-up will look like there? And any incremental data we may see? And then, my second question is, considering the data we've seen within the Phase 1 breast cancer study and now that it's fully enrolled, can you discuss your current thoughts around next steps within breast cancer? Or if you're planning on pivoting to a different indication within the solid tumor space? Thank you.

Jim Breitmeyer -- Chief Executive Officer

Thanks for the question, Rob. I'll answer the second one first and then turn over to Salim for the first one. So breast cancer is going to be one of -- probably at this point, first among several indications that we're looking at in this strategic planning process. And so we are -- we really like the breast cancer results, and they're very encouraging, apparently, double the objective responses compared to paclitaxel alone with a good safety profile.

So that is -- that's certainly something that we'll think hard about building on. So let me turn it over to Salim as far as how much follow-up and what we may be presenting in our next interim update. 

Salim Yazji -- Chief Medical Officer

Yes. Thank you, Jim. Actually, I mean, what's gonna happen is we most likely gonna present the data at the next scientific conference. And as you know, we only can present the evaluable patients.

They have to have at least one evaluation after two months of treatment. So we would expect probably a handful of patients, additional patients to be presented at the end of the quarter. As you know now, we only have 18 evaluable patients for MCL and 34 evaluable patients for CLL. So for CLL, we're not gonna have any more patients, but we will have 18 evaluable operations, more than 18 evaluable patients by the end of the quarter. 

Robert Burns -- H.C. Wainwright & Co. -- Analyst

Awesome. Thanks for the color there, guys.

Jim Breitmeyer -- Chief Executive Officer

Sure. Thank you, Rob. 

Operator

Thank you. Our next questions come from the line of Carl Byrnes with Northland Securities. Please proceed with your questions.

Carl Byrnes -- Northland Securities -- Analyst

Great, thank you, and congratulations on all the progress. Obviously, a number of conferences toward the end of the year, ASH in December, the San Antonio Breast Cancer Symposium also, I believe, in early December and then the CTOS symposium in November. Would you anticipate any presentations prior to those events? And if so, what events might they be? Thanks.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Carl. And you did name the most likely venues for us to present in the fourth quarter. We've presented before their high profile, their great conferences. At this point, we don't have anything before that on the books.

But we always keep our eyes open for opportunities to try to give updates when we can.

Carl Byrnes -- Northland Securities -- Analyst

Great, thanks. That's helpful. And also, looking back to cirmtuzumab for MCL with respect to registrational trial, just kind of assuming for the moment that the PFS number that we find is very high, what might be done in terms of a trial design that wouldn't penalize you, if you will, for having a long PFS? In other words, if we want to accelerate something to market and you've got obviously PFS, progression free survival of two times, what could be done there? Thanks.

Jim Breitmeyer -- Chief Executive Officer

Yes. So great question, Carl. And so what we think is particularly interesting is that we've got a strong objective response rate, and that is an endpoint that has been accepted by the FDA previously for accelerated approval. And then, we have this substantial improvement in progression-free survival, which is an endpoint that has been accepted for full approvals.

And so we're considering that certain patients with MCL on ibrutinib have a shorter progression-free survival than average. And so we may be able to further accentuate the difference in PFS by enrolling a population of MCL patients with unmet medical need. 

Carl Byrnes -- Northland Securities -- Analyst

And then, would you also potentially be able to follow that up with kind of a post surveillance for other patient populations to achieve kind of a more reflective PFS?

Jim Breitmeyer -- Chief Executive Officer

Yes. The short answer is yes. 

Carl Byrnes -- Northland Securities -- Analyst

Cool. Great. Thanks so much. That's helpful. 

Jim Breitmeyer -- Chief Executive Officer

Thank you, Carl.

Operator

Thank you. [Operator instructions] Our next questions come from the line of Kumar Raja with Brookline Capital Markets. Please proceed with your questions. 

Kumar Raja -- Brookline Capital Markets -- Analyst

Thanks for taking my questions. With regard to the breast cancer trial, what do we know about the ROR1 expression in the patients who had a partial response? And also, how does the treatment impact their ROR1 expression? 

Jim Breitmeyer -- Chief Executive Officer

Salim? 

Salim Yazji -- Chief Medical Officer

Yeah, so you're talking about the expression of ROR1 and tumor type? Just to clarify the question. 

Kumar Raja -- Brookline Capital Markets -- Analyst

Yeah, I understand that in the breast cancer trial, all of them had ROR1 expression based on IHC. My question is like, is there a cutoff point where you're seeing the partial responses and whether this can be optimized in a future trial, so that you are selective for patients whom you think would be responsive? 

Salim Yazji -- Chief Medical Officer

Yeah, so just to actually kind of like confirm one point here, so the breast cancer study, it's an investigator-initiated study. But what we know is 100% of the patients who have been enrolled in the study have a ROR1 expression. And those patients actually have been heavily treated with a median, about six prior therapy for their metastatic disease. So when we try to enroll our patients, we try really to make sure that they have actually a ROR1, at least, expression because that's where the signs and the -- our antibody will work. 

Kumar Raja -- Brookline Capital Markets -- Analyst

Is there a particular level of ROR1 expansion you are looking at like 50% of the cells? Or is there any cutoff like that? 

Salim Yazji -- Chief Medical Officer

Yes. So as Jim mentioned earlier, actually, we're gonna do an exercise for multiple tumor types, and we were gonna be ranking them about -- from multiple angles. And then we will choose the optimal tumor types that we're going to go forward with. 

Kumar Raja -- Brookline Capital Markets -- Analyst

In terms of potential combination -- yeah, please go ahead. 

Jim Breitmeyer -- Chief Executive Officer

Yeah, Kumar, to your specific question, the immunohistochemistry method has been -- it's been going -- undergoing method improvements over the course of the study. And so far, what we understand is that there's -- there hasn't been any correlation with the brightness of the ROR1 signal or the number of cells and the clinical response. 

Kumar Raja -- Brookline Capital Markets -- Analyst

OK. And in terms of the potential combinations, what do we know in terms of like how these combinations are sequencing? What kind of impact they have on the ROR1 expression? Thank you.

Jim Breitmeyer -- Chief Executive Officer

Sure. So in a number of cases, there is evidence accumulating that ROR1 expression increases with each course of therapy for both hematologic and solid tumors. And the part of the ROR1 biology is that it is characteristic ROR1 expression is correlated, associated with a primitive phenotype, and that primitive type is also characteristic of drug-resistant cancer. So we do think that the ROR1 expression does go along with resistance to conventional therapy.

And there are several cases that we're exploring further now where there is a potential to either get an additive or synergistic effect with the next treatment or some interesting preliminary data that we're still working on to suggest that ROR1 inhibition may return tumor cells to a sensitive reaction to a therapy that they were previously resistant to. So those are the sorts of things that we're looking hard at. 

Kumar Raja -- Brookline Capital Markets -- Analyst

And in terms of the combination with venetoclax, what is the reason there? Thank you. 

Jim Breitmeyer -- Chief Executive Officer

Salim? 

Salim Yazji -- Chief Medical Officer

Yep. So actually, I mean, we are looking into multiple combination options. I mean, based on who are preclinical studies like venetoclax is one of them, I mean, paclitaxel and the others, and plus, other things that still are going now under investigation. I mean, the nice thing about our drug is it's actually the low-toxicity profile that make it very much combinable with a lot of other drugs that have been approved for treatment of a specific line of therapy. 

Kumar Raja -- Brookline Capital Markets -- Analyst

No, my question is with regard to any update in terms of enrollment or it's all mostly investigator-driven, and you can't say anything at this point. 

Salim Yazji -- Chief Medical Officer

So are you talking about the investigational-sponsored study with venetoclax? 

Kumar Raja -- Brookline Capital Markets -- Analyst

Yes. 

Salim Yazji -- Chief Medical Officer

Yeah, so so far, we have only four patients, and we don't have any specific information there. As the enrollment there, it's not going as fast as we would like it to, but we have four patients in the study so far. 

Kumar Raja -- Brookline Capital Markets -- Analyst

OK, great. Thank you so much.

Salim Yazji -- Chief Medical Officer

You're welcome.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Kumar. 

Operator

[Operator signoff]

Duration: 39 minutes

Call participants:

Rich Vincent -- Chief Financial Officer

Jim Breitmeyer -- Chief Executive Officer

Salim Yazji -- Chief Medical Officer

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Robert Burns -- H.C. Wainwright & Co. -- Analyst

Carl Byrnes -- Northland Securities -- Analyst

Kumar Raja -- Brookline Capital Markets -- Analyst

More ONCT analysis

All earnings call transcripts

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Oncternal Therapeutics, Inc. Stock Quote
Oncternal Therapeutics, Inc.
ONCT
$1.07 (-0.93%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.